


[illegible][illegible]

Examiner Signature	/Yong Chu/	Date Considered	11/02/2006
--------------------	------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 			COMPLETE IF KNOWN		
			Application Number	10/523,286	
			Filing Date	February 3, 2005	
			First Named Inventor	Christopher J. Dinsmore	
			Group Art Unit	To Be Assigned	
			Examiner Name	To Be Assigned	
Sheet	1	of	2	Attorney Docket Number	21007YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
YC	1	Arteaga, C. L. et al., "Blockade of the Type 1 Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice", J. Clin. Invest, Vol. 84, pp. 1418-1423 (1989)
	2	Baserga, R., "Controlling IGF-receptor function: a possible strategy for tumor therapy", Trends in Biotechnology (TIBTECH), Vol. 14, pp. 150-152 (1996)
	3	Baserga, R., "Oncogenes and the Strategy of Growth Factors", Cell, Vol. 79, pp. 927-930 (1994)
	4	Baserga, R., "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?", Cancer Research, Vol. 55, pp. 249-252 (1995)
	5	Bolen J. B. et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction", The FASEB Journal, Vol. 6, pp. 3403-3409 (1992)
	6	Cance W. G., et al., "NOVEL PROTEIN KINASES EXPRESSED IN HUMAN BREAST CANCER", Int. J. Cancer, Vol. 54, pp. 571-577 (1993)
	7	Coppola, D., et al., "A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor", MOLECULAR AND CELLULAR BIOLOGY, Vol. 14, pp. 4588-4595 (1994)
	8	Goldring, M. B., et al., "Cytokines and Cell Growth Control", Eukaryotic Gene Expression, Vol. 1, pp. 301-326 (1991)
	9	Kenyon, C., et al., "A Conserved Regulatory System for Aging", Cell, Vol. 105, pp. 165-168 (2001)
	10	Khandwala, H. M., et al., "The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth", Endocrine Reviews, Vol. 21, pp. 215-244 (2000)
	11	Kimura, K. D., et al., "daf-2, an Insulin Receptor-Like Gene That Regulates Longevity and Diapause in Caenorhabditis elegans", SCIENCE, Vol. 277, pp. 942-946 (1997)
	12	Macaulay, V. M., et al., "Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells", Cancer Research, Vol. 50, pp. 2511-2517 (1990)
	13	Minet et al., "Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (Review)", International Journal of Molecular Medicine, Vol. 5, pp. 253-259 (2000)
✓	14	Plowman, G. E., et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention", DN&P, Vol. 7, pp. 334-339 (1994)
YC	15	Sandberg-Nordqvist, A. C., et al., "Characterization of Insulin-like Growth Factor 1 in Human Primary Brain Tumors", Cancer Research, Vol. 53, pp. 2475-2478 (1993)

Examiner Signature	/Yong Chu/	Date Considered	11/02/2006
--------------------	------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PFO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/523,286
Filing Date	February 3, 2005
First Named Inventor	Christopher J. Dinsmore
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	21007YP

Sheet	2	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	/Yong Chu/	Date Considered	11/02/2006
-----------------------	------------	--------------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003